ArticleCellular and molecular gastroenterology and hepatology2026
Overlapping Yet Distinct Functions of Vacuole Membrane Protein 1 and Transmembrane Protein 41B in Modulating Hepatic Lipoprotein Secretion and Autophagy.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Loss of Vacuole Membrane Protein 1 protects against acetaminophen-induced liver injury by modulating inflammation and hepatocyte proliferation.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Vacuolar Membrane Protein 1 and Transmembrane Protein 41B in Action: At the Right Place, With the Right Strength.Cellular and molecular gastroenterology and hepatology · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND &
aimsTransmembrane protein 41B (TMEM41B) and vacuolar membrane protein 1 (VMP1) are endoplasmic reticulum (ER) scramblases whose roles in hepatic lipoprotein secretion and autophagy in metabolic-associated steatotic liver disease (MASLD) remain unclear.
methodsWe undertook lipidomic and functional studies in liver- and hepatocyte-specific Tmem41b knockout (KO) mice; Tmem41b knock-in (KI) mice, Tmem41b/Vmp1 double KO (DKO); Tmem41b KO/Vmp1 KI, and Vmp1 KO/Tmem41b KI mice.
resultsTMEM41B protein levels decreased in the livers of human subjects with MASLD. Loss of hepatic Tmem41b impaired very low-density lipoprotein (VLDL) secretion, with steatosis, inflammation, and fibrosis, whereas hepatic TMEM41B overexpression mitigated these effects. Tmem41b/Vmp1 DKO mice showed further impairment in VLDL secretion compared with single Tmem41b KO. Lipidomic analysis revealed decreased phosphatidylcholine and phosphatidylethanolamine, with increased neutral lipids in Tmem41b KO mice. VMP1 and TMEM41B localize at the mitochondrial-associated membrane with reduced mitochondria-ER contact in Vmp1 and Tmem41b KO mice. Loss of hepatic VMP1 or TMEM41B increased levels of LC3B-II and p62/SQSTM1, which were not further changed in DKO mice. Restoring VMP1 in Tmem41b KO mice and TMEM41B in Vmp1 KO mice partially corrected defective VLDL secretion and hepatic steatosis in these single KO mice, respectively. Restoring VMP1 at a low but not a high dose corrected defective autophagy in Tmem41b KO mice, whereas overexpression of TMEM41B dose-dependently improved defective autophagy in Vmp1 KO mice.
conclusionsLoss of hepatic VMP1 or TMEM41B reduces VLDL secretion and promotes MASLD via overlapping but distinct mechanisms that regulate lipoprotein secretion and autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.